top of page


Snapdragon Chemistry’s main focus is to deliver value to our clients. Thus, we have partnered with trusted, cutting-edge organizations that complement our skill sets and services, to provide the best solutions to our clients.



Asymchem (stock code: 002821.SZ) is a leading global integrated CDMO service provider of innovative drug R&D and manufacturing with 5000 employees based in China, the US, and the EU. 

The combination of Snapdragon's technology and process development capabilities, along with Asymchem's expertise in clinical and commercial manufacturing provides our clients with a complete solution to drug development.


Zaiput Flow Technologies

Zaiput Flow Technologies is dedicated to bringing innovative tools for continuous flow to the market. Zaiput specializes in modular liquid-liquid separators and back pressure regulators for a variety of flow rates and with robust designs for harsh chemistries.

Through our partnership with Zaiput Flow Technologies, we will bring the most innovative and effective continuous flow technology to our clients. Zaiput and Snapdragon Chemistry are co-located in the Boston area, enabling us to collaborate efficiently to build cutting-edge reactor systems for continuous flow synthesis.


Paraza Pharma, Inc

Paraza Pharma, Inc. is an innovative company with an aim to improve significantly the efficiency of the drug discovery process from lead identification through lead optimization to development candidates.

Paraza complements Snapdragon Chemistry’s expertise in drug discovery and enables us to provide more holistic, innovative solutions to our clients in the discovery and early development space. Our combined insights, experience, and workforce help power an integrated solution that can completely transform productivity in discovery.


Usher III Initiative

The Usher III Initiative is a non-profit organization dedicated to finding therapies for patients with Usher syndrome type III, a rare genetic disorder that causes the progressive loss of both hearing and sight. Although typically born with normal vision and hearing, by mid-life, those afflicted with this devastating orphan disease are profoundly deaf and legally blind. For the past 17 years, the Initiative has focused on collaborative, therapy-directed, academic and industry research projects to investigate the cause of and a cure for Usher III. Through these efforts, the Initiative has discovered a proprietary compound, currently being manufactured in partnership with Snapdragon Chemistry, which will be developed as a potential treatment. With Snapdragon’s help, the Initiative is closer than ever to achieving its goal!

bottom of page